KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
N0 neck trial: Does intensification of follow-up (Ultrasound + Physical Examination) influence outcomes in early-stage oral cancer? PMID 38705028 · Eur J Cancer · 2024-Jun The record is a randomized trial of human oral cancer with a primary OS endpoint and original results, but it does not involve a drug-containing intervention (surgical/follow-up only).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of remote ischemic preconditioning intervention on serum levels of microRNA-582-5p/HMGB1 in patients with acute cerebral infarction. PMID 38701547 · Clin Neurol Neurosurg · 2024-Jun The study is a randomized controlled trial on human patients with results, but it is not an oncology study (focused on acute cerebral infarction). It does not involve a drug-containing intervention (the intervention is remote ischemic preconditioning, a procedure). It does not report a primary/key secondary time-to-event efficacy endpoint. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. PMID 38689060 · Nat Med · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial. PMID 38664577 · Br J Cancer · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A digital, coach-assisted intervention to address the psychosocial needs of young adult cancer survivors: Randomized controlled trial protocol and intervention adaptation process. PMID 38657732 · Contemp Clin Trials · 2024-Jun This is a protocol for a randomized controlled trial in young adult cancer survivors, but it presents no efficacy results, is not a Phase III/IIIb or Phase II/III drug trial, and does not report a time-to-event primary/key secondary efficacy endpoint (like OS or PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Localized colorectal cancer database integrating 4 randomized controlled trials; (JCOG2310A). PMID 38657376 · Eur J Surg Oncol · 2024-Jun The record is not an original formal-result report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. It describes the establishment of a database integrating data from multiple prior trials for ancillary studies.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial. PMID 38636289 · Eur J Cancer · 2024-Jun This is a subgroup analysis of the RAPIDO trial focusing on patients who achieved a pathological complete response. While the trial itself is a Phase III randomized trial (which could make it eligible), the presented report analyzes a pre-selected subgroup, not the primary full-cohort efficacy results. The deterministic review flagged phase evidence as unclear, but the main reason for exclusion is the subgroup nature of the analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). PMID 38630385 · J Neurooncol · 2024-Jun The record describes a combined secondary analysis of two randomized trials (GEINO1401/EX-TEM) exploring outcomes by age. While it reports time-to-event endpoints (PFS, OS) and includes drug interventions, it is not a primary result report of a single Phase III/IIIb or Phase II/III trial. The trial phase of the underlying studies is not explicitly stated in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies. PMID 38625671 · Rheumatol Ther · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex. PMID 38619178 · J Dermatol · 2024-Jun The study is an original Phase III randomized controlled trial of a drug (sirolimus) for an oncology-related condition, but the primary efficacy endpoint is a non-time-to-event composite score (FASI/IFA) with no reported time-to-event analysis (OS, PFS, etc.) or Kaplan-Meier/HR data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Colonoscopy Outreach for Rural Communities (CORC): A study protocol of a pragmatic randomized controlled trial of a patient navigation program to improve colonoscopy completion for colorectal cancer screening. PMID 38615750 · Contemp Clin Trials · 2024-Jun 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. PMID 38615483 · Breast · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. PMID 38602625 · Invest New Drugs · 2024-Jun This is a Phase I-type pharmacokinetic food-effect study in healthy volunteers, not a Phase II/III randomized trial in cancer patients with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. PMID 38584004 · Clin Genitourin Cancer · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intradermal acupuncture in the treatment of rheumatoid arthritis with liver and kidney deficiency syndrome - A sham-controlled, randomized, clinical trial. PMID 38582376 · Complement Ther Med · 2024-Jun The study is a randomized controlled trial in humans with original results, but it is not an oncology study (rheumatoid arthritis), does not involve a drug intervention (intradermal acupuncture), and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are clinical scores and biomarkers (TCM syndrome evaluation, HAQ, DAS28, CRP).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy. PMID 38572570 · Prostate · 2024-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma. PMID 38553363 · Clin Oncol (R Coll Radiol) · 2024-Jun Phase II randomized trial of radiotherapy dose escalation (non-drug intervention) in high-risk neuroblastoma; not Phase III/IIIb, lacks a drug-containing intervention, and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The application of enhanced recovery after surgery protocol after distal gastrectomy for patients with gastric cancer: a prospective randomized clinical trial. PMID 38538479 · J Gastrointest Surg · 2024-Jun This is a randomized controlled trial in oncology (gastric cancer) with original results, but it is excluded because it does not meet two key criteria: (1) The intervention is a non-drug-only enhanced recovery after surgery (ERAS) protocol, and (2) the primary/key secondary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are postoperative hospital stay, recovery metrics, and quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. PMID 38537780 · J Thromb Haemost · 2024-Jun The record is a randomized trial in oncology with time-to-event results, but the required Phase III/IIIb or Phase II/III evidence is not explicitly established in the provided metadata or abstract text. Therefore, it is not eligible for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). PMID 38528813 · CPT Pharmacometrics Syst Pharmacol · 2024-Jun While the record is from a randomized, drug-intervention oncology trial, it is a pharmacokinetic-pharmacodynamic modeling study that does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier data or hazard ratios. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-World experience with efgartigimod in patients with myasthenia gravis. PMID 38528163 · J Neurol · 2024-Jun 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009. PMID 38527954 · Br J Haematol · 2024-Jun Report is an observational analysis of an infectious complication within a randomized trial, not a primary or secondary report of the trial's time-to-event efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. PMID 38525811 · J Pathol · 2024-Jun The record is an oncology study involving human patients and includes anti-PD-L1 drug therapy with a phase III publication type. However, it is not eligible because it lacks an explicit primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting. The study focuses on developing and validating automated immunophenotyping methods as predictive biomarkers, not on reporting the efficacy results of a randomized clinical trial. The randomized status is not explicitly established, and the report type is a methodological/biomarker analysis rather than an original trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma. PMID 38519329 · Clin Lymphoma Myeloma Leuk · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. PMID 38500292 · J Cachexia Sarcopenia Muscle · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial. PMID 38494565 · Ann Surg Oncol · 2024-Jun The record describes a randomized trial for melanoma with a primary time-to-event endpoint (DFS) and reports formal results. However, the trial compares surgical extents (inguinal vs. ilio-inguinal lymphadenectomy) and does not involve a drug-containing intervention. The trial phase is not explicitly confirmed as Phase III or definitive in the provided metadata. Therefore, it does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia. PMID 38494194 · Br J Haematol · 2024-Jun While the record describes a randomized, Phase II/III oncology trial with a drug intervention, it reports pharmacokinetic modeling results, not time-to-event efficacy outcomes (OS, PFS, DFS, EFS, RFS, TTP, KM, HR). Therefore, it does not meet the required primary/key secondary endpoint criterion for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical and biochemical assessment of the effect of glutamine in management of radiation induced oral mucositis in patients with head and neck cancer: Randomized controlled clinical trial. PMID 38493953 · J Stomatol Oral Maxillofac Surg · 2024-Jun The study is an oncology RCT with a drug intervention (glutamine) and reports original results, but it does not have a time-to-event efficacy endpoint. The primary endpoints are biochemical (salivary TGF-β1 levels) and clinical toxicity/quality-of-life measures (oral mucositis severity, pain, opioid use), not survival or disease progression. Therefore, it does not meet the eligibility criteria for KM digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial). PMID 38493679 · Eur J Surg Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. PMID 38490927 · Clin Lymphoma Myeloma Leuk · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. PMID 38459418 · Ann Surg Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. PMID 38453781 · Breast Cancer Res Treat · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes. PMID 38446316 · Breast Cancer Res Treat · 2024-Jun The study is a randomized, human, oncology trial evaluating a dietary intervention alongside systemic therapy for metastatic breast cancer. It meets criteria for oncology, human subjects, randomization, and drug intervention (systemic therapy is part of the standard of care). It is an original result report. However, it is excluded because it lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) with Kaplan-Meier or HR reporting; its primary outcomes are cardiometabolic and hormonal parameters. Additionally, the phase is not specified as Phase III or definitive (Phase II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial. PMID 38436921 · J Gastrointest Cancer · 2024-Jun The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (RFS), but the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata. While it meets several criteria (oncology, human, randomized, drug intervention, time-to-event, original result), the absence of clear phase III evidence means the 'phase3_or_definitive' criterion cannot be confirmed, making the record ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intermediate-Term Oncologic Outcome Assessment for Robot-Assisted Radical Prostatectomy: Comparing Retzius-Sparing with Standard Approach in a Randomized Control Cohort. PMID 38429913 · J Endourol · 2024-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. PMID 38423389 · Ann Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial. PMID 38422947 · Gynecol Oncol · 2024-Jun The study is a randomized oncology trial in humans, but it evaluates a non-drug weight management intervention and does not report a standard time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio. The primary outcome is complete remission rate, not a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Is cryoablation still suitable for advanced non-small cell lung cancer after failure of first-line chemotherapy? A multicenter, prospective, randomized-controlled trial of eighty-seven patients. PMID 38387752 · Cryobiology · 2024-Jun The study is an oncology, human, randomized controlled trial with a time-to-event primary endpoint (overall survival). However, the intervention is cryoablation, which is a device/procedural intervention, not a drug-containing intervention as required by the cohort criteria. Phase evidence is also not explicitly established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP. PMID 38380861 · Leuk Lymphoma · 2024-Jun This is a subgroup analysis, not the primary report of the randomized trial, and the definitive trial phase is not established from the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001). PMID 38374403 · Cancer Chemother Pharmacol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Childbirth experiences in women with polycystic ovary syndrome: A cohort study. PMID 38366810 · Acta Obstet Gynecol Scand · 2024-Jun 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial. PMID 38348547 · BJU Int · 2024-Jun The record describes a randomized trial of a device (nerve monitoring) versus standard surgical care in prostate cancer surgery. While it is an oncology randomized trial with original results, it fails two key eligibility criteria: 1) The intervention is a surgical device/technique, not a drug-containing intervention. 2) The primary efficacy endpoint is a patient-reported quality-of-life score (ICIQ-SF) at 12 months, not a time-to-event endpoint like OS, PFS, or DFS. The reported continence rates at time points are secondary and not presented as time-to-event analysis (e.g., Kaplan-Meier curves, hazard ratios). Phase is not specified, but this is not the primary reason for exclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Smoking Cessation by Cancer Treatment Status Among Cervical Cancer Survivors. PMID 38342477 · Am J Prev Med · 2024-Jun The record is excluded because it does not meet all required criteria for inclusion. While it is an original, randomized, oncology, human trial, it fails on two key criteria: it is not a drug intervention (it tests a behavioral counseling program) and it does not report a time-to-event efficacy endpoint (it reports 12-month smoking abstinence).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy. PMID 38316611 · BJU Int · 2024-Jun Study is randomized and in oncology patients, but the intervention is non-drug (acupuncture) and the primary endpoint is a patient-reported pain score (NRS-11), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest. PMID 38286499 · Clin Exp Emerg Med · 2024-Jun The study is a randomized trial of a drug (amantadine) in human subjects with results, but it is not an oncology trial; it investigates coma awakening after cardiac arrest. No oncologic condition or oncology-specific time-to-event efficacy endpoint is present.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of an E-learning resource on endoscopists' proximal serrated polyp detection rate: a randomized controlled trial. PMID 38191001 · Endoscopy · 2024-Jun The study is an oncology-related randomized trial on colorectal cancer screening, but it evaluates an e-learning intervention (non-drug) and uses a binary detection rate as the primary endpoint, not a time-to-event outcome like OS, PFS, DFS, etc., nor does it report Kaplan-Meier curves or hazard ratios. Phase is not specified as definitive Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial? PMID 38141577 · Respir Med Res · 2024-Jun The record is a retrospective observational study assessing eligibility of clinical practice patients for two prior RCTs. It is not a primary report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The study itself is not randomized and does not report the results of a drug intervention trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. PMID 38095652 · Naunyn Schmiedebergs Arch Pharmacol · 2024-Jun This is an original, randomized trial in an oncology (acute myeloid leukemia) population with a drug intervention (atorvastatin). However, the trial is not explicitly identified as Phase III/IIIb or a definitive Phase II/III, and the primary efficacy endpoint is IFI-free survival (a composite infection endpoint), not a standard oncology time-to-event endpoint like OS, PFS, DFS, etc. The abstract does not mention Kaplan-Meier curves or hazard ratios for a cancer-related endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Successful EUS-guided pancreatic cyst chemoablation safely allows reduction in the frequency of radiographic surveillance: long-term follow-up of randomized prospective data. PMID 38092127 · Gastrointest Endosc · 2024-Jun This is a long-term follow-up of randomized trials evaluating a chemoablation procedure and subsequent surveillance protocol for pancreatic cysts. While it involves oncology, human subjects, randomization, and drug intervention (chemoablation), the primary endpoints are radiographic response/durability, economic outcomes, and patient experience. There is no explicit time-to-event efficacy endpoint (like OS, PFS, DFS) or associated Kaplan-Meier/HR data. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for a time-to-event efficacy endpoint from a definitive-phase randomized drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. PMID 38061976 · Eur Urol Oncol · 2024-Jun 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -